Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 16/20 | 0.43 |
| ▸ | MC5R | P33032 | 8/20 | 0.43 |
| ▸ | MC3R | P41968 | 6/20 | 0.43 |
| ▸ | MC1R | Q01726 | 4/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | PYGM | P11217 | 1/20 | 0.42 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13968044 | 0.90 | PYGL (0.42) | MC4RMC5RMC3RMC1RPYGL | |
| SCHEMBL14400979 | 0.87 | CYP51A1 (0.48) | MC4RMC5RMC3RMC1RPYGL | |
| SCHEMBL2606904 | 0.76 | CYP51A1 (0.56) | PYGLPYGMCYP51A1KMT2A | |
| SCHEMBL13271677 | 0.75 | MC4R (0.44) | MC4RMC5RMC3RMC1RPYGL | |
| SCHEMBL2608607 | 0.74 | MMP9 (0.46) | MC4RPYGL | |
| SCHEMBL13271500 | 0.72 | PYGL (0.41) | MC4RMC5RMC3RMC1RPYGL | |
| SCHEMBL13271678 | 0.72 | CYP51A1 (0.48) | MC4RMC5RMC3RMC1RPYGL | |
| SCHEMBL2606799 | 0.70 | CYP51A1 (0.56) | PYGLPYGMCYP51A1KMT2A | |
| SCHEMBL2606846 | 0.70 | CYP51A1 (0.61) | PYGLPYGMCYP51A1 | |
| SCHEMBL13271644 | 0.70 | PYGL (0.41) | MC4RMC5RMC3RMC1RPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | MC4R 4127/4885MC5R 4201/4885MC3R 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.